34482Looking for health insurance? Treatment cost of these maladies will not be covered!

Thyrocare Technologies rose 1.46% to Rs 1,074.45 after the company reported a consolidated net profit of Rs 37.75 crore in Q4 FY21 compared with a net loss of Rs 1.60 crore in Q4FY20.

Net sales during the quarter increased 44.8% year-on-year (YoY) to Rs 146.84 crore. On the segmental front, revenue from diagnostic testing services was at Rs 138.68 crore (up 49.4% YoY), revenue from imaging services was at Rs 7.68 crore (down 5.2% YoY) in the fourth quarter.

Profit before tax stood at Rs 47.63 crore in Q4 FY21, up 171.2% from Rs 17.56 crore in Q4 FY20.

Current tax outgo jumped by 48% to Rs 14.37 crore in Q4 FY21 over Q4 FY20.

Thyrocare reported a 28% rise in consolidated net profit to Rs 113.14 crore on a 14.2% increase in net sales to Rs 494.62 crore in the year ended 31 March 2020.

The company’s board has recommended a dividend of Rs 15 per share.

Thyrocare Technologies operates a chain of diagnostic and preventive care laboratories.

Powered by Capital Market – Live News